Many low-and lower-middle-income countries currently procure a large portion of their health products—drugs, devices, diagnostics, and vector control tools— through centralized, donor-managed mechanisms, and often at subsidized prices or as donations. Moreover, global health procurement needs are evolving rapidly as countries face the prospect of transitioning from donor aid, global disease burdens shift, and the organization of health systems shifts from vertical disease programs to universal health coverage.
In this context, how can the global health community act now to ensure the medium- to-long-term efficiency, quality, affordability, and security of global health procurement? This question was the subject of CGD’s Working Group on the Future of Global Health Procurement. The final report is available here.
For more related research from our experts and partners, click here.